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BACKGROUND Portico (St. Jude Medical) and CoreValve (Med-
tronic) are both nitinol based self-expanding transcatheter heart valves
with unique features enabling device retrievability for Portico and su-
pra annular valve position for CoreValve systems. In this study, we
sought to investigate the effect of the different self-expanding valve
design on hemodynamic and clinical performance when implanted for
degenerated aortic valve bioprosthesis (valve in valve, ViV).
METHODS Patients undergoing Portico implantation for degenerated
aortic bioprosthesis were compared to those undergoing CoreValve
implantation after matching for differences in age, gender, STS score,
arterial access, bioprosthesis valve design and label size in a 1:2
manner. Procedural and clinical outcomes were deﬁned by Valve
Academic Research Consortium II (VARC-II).
RESULTS A total of 135 patients that underwent ViV using a self-
expanding device were included in the analysis (age 798yrs, 61.5%
female). The group included 45 Portico implantations that were
matched with 90 CoreValve ViV patients having similar patient and
surgical valve characteristics. Baseline demographic and procedural
characteristics, echocardiographic and clinical outcomes are detailed
in the table. There were no differences in any procedural character-
istics between the two groups, except for the external transcatheter
valve diameter selected being signiﬁcantly greater for the CoreValve
ViV and proportion of patients undergoing procedure under
general anesthesia and with TEE guidance, which was signiﬁcantly
higher for the Portico group. Clinical outcomes were similar except
for major vascular complications that were signiﬁcantly lower in
Portico implantations. Site reported echocardiographic parameters
showed a greater proportion of patients with more than mild aortic
insufﬁciency after the procedure and a smaller effective oriﬁce area
for the Portico compared to CoreValve group. Blinded core lab analysis
of post implantation imaging of all cases analyzed is being completed.CONCLUSIONS Despite important design differences between the
two self-expanding transcatheter valves, both devices were safe
and effective for management of degenerated aortic bioprosthesis.
The present study has identiﬁed dissimilarities in hemodynamic
performance and clinical outcomes that require conﬁrmation in
future studies.Portico
(n[45)CoreValve
(n[90) P valueBaseline characteristicsSTS score, mean  SD 7.5  3.7 8.1  5.2 0.11
THV external
diameter, mean 
SD24  1 26  2 <0.05Clinical outcomes at 30 daysDeath, n (%) 1 (2.2) 4 (4.7) 0.5Stroke, n (%) 1 (2) 2 (2) 1Major vascular
complication, n (%)1 (2) 8 (9) 0.03Coronary obstruction
(%)0 (0) 4 (4.6) 0.30Malposition, n (%) 0 (0) 5 (6.0) 0.16Second prosthesis, n
(%)0 (0) 5 (5.6) 0.17Permanent pacemaker,
n (%)1 (3) 5 (6) 0.67> Mild aortic
insufﬁciency n (%)8 (18) 4 (5) 0.02EOA cm2, mean  SD 1.3  0.4 1.5  0.4 0.03
Mean gradient mmHg ,
mean  SD
17.1 8 15.5 8 0.30AKI- Acute Kidney Injury, EOA-effective oriﬁce area, PPM-permanent pacemaker, LVEF-left ventricle ejection
fraction, STS-Society of Thoracic Surgery score, TEE-transesophageal echocardiography, THV- Transcatheter
Heart Valve.
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BACKGROUND Transcatheter aortic valve replacement (TAVR) has
been established as alternative treatment for inoperable or high-risk
patients with symptomatic severe aortic stenosis. We sought to
evaluate the clinical outcomes of TAVR in Asian Paciﬁc countries.
METHODS The Asian TAVR registry was conducted in 12 centres from
6 countries between February 2009 and February 2015. Baseline de-
mographics, procedural and echocardiographic data were prospec-
tively collected from each center and entered into dedicated
electronic case report form.
RESULTS Nine hundred and forty patients were included. Mean
age was 82.1  6.5 years and 52.9% were female. Edwards SAPIEN/XT
and CoreValve were used in 65.4% and 34.6% of patients, respec-
tively. Approaches were either transarterial (transfemoral, 85.8%;
subclavian, 0.4%; direct aortic, 1.6%) or transapical (12.0%).
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(EuroSCORE) and Society of Thoracic Surgeons (STS) score were
21.6  15.5 and 7.0  5.6, respectively. Rates of death at 30 days and
1 year were 3.4% and 10.6%, respectively. At 30 days, the incidence
of all stroke, major vascular complications, life-threatening
bleeding, and acute kidney injury (stage 2 or 3) were 3.0%, 5.2%, 7.6%
and 4.2%, respectively. Paravalvular regurgitation moderate or
greater occurred 9.5%. Device success rate and combined safety
endpoint at 30 days were 86.2% and 81.0%, respectively. In a multi-
variate model, female, chronic kidney disease, diabetes mellitus,
pulmonary disease, peripheral vascular disease, paravalvular regur-
gitation mild or greater, and STS score were signiﬁcantly associated
with reduced survival.
CONCLUSIONS This registry reﬂects the real-life experience of TAVR
in patients with increased risk in Asian Paciﬁc countries.
Clinical outcomes of TAVR in Asian Paciﬁc countriesOverall
(N [ 940)SAPIEN/XT
(N [ 615)CoreValve
(N[ 325) p valueMortality at 30
days3.4% 4.0% 2.5% 0.23Mortality at 1
year10.6% 7.6% 14.5% 0.02All stroke 3.0% 2.8% 3.4% 0.69Life-threatening
bleeding7.6% 8.1% 6.5% 0.36Acute kidney
injury stage 2-
34.3% 3.6% 5.5% 0.16Major vascular
complications5.2% 6.0% 3.7% 0.13Device success 86.2% 90.6% 78.1% < 0.001Safety endpoint 81.0% 80.3% 82.2% 0.51CATEGORIES STRUCTURAL: Valvular Disease: Aortic
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BACKGROUND High surgical risk and inoperable patients with severe
aortic stenosis (AS) undergoing TAVR often have reduced baseline
renal function. The impact of TAVR on improving this reduced base-
line renal function is unknown.
METHODS All patients undergoing TAVR from the PARTNER 1A (high
surgical risk), PARTNER 1B (inoperable), and both the randomized and
non-randomized continued access cohorts with glomerular ﬁltration
rate (GFR, utilizing the modiﬁcation of diet in renal disease formula) 
60 mL/min were analyzed. Patients were categorized as improved
GFR (30-day follow-up GFR 10% higher than baseline pre-TAVR
GFR), worsened GFR (30-day follow-up GFR 10% lower than baseline
pre-TAVR GFR), or no signiﬁcant change (not ﬁtting either previous
group). Baseline characteristics and 1-year all-cause mortality, as well
as repeat hospitalization rates, were compared between groups. Cox
regression models were used to determine multivariable predictors of
all-cause 1-year mortality.
RESULTS In total, 822 patients were analyzed, of which 345 (42%)
showed an improvement in GFR, 197 (24%) had worsening in GFR, and
280 (34%) had no signiﬁcant change in GFR. Comparing patients with
improved GFR with those with worsening GFR and those with no
signiﬁcant change in GFR, there was no difference in the mean age,
BMI, diabetes mellitus, COPD, CAD, PAD, pulmonary hypertension,
renal disease (Cr> 2 mg/dl), NYHA class III or IV symptoms, liver
disease, mean transaortic gradient, mean cardiac index, or mean
baseline EF. The improved GFR group had a greater percentage of
females (55.1% for improved GFR group vs. 40.1% for worsened GFR
group vs. 47.1% for no change group, p<0.01), lower median STS score
(10.9 vs. 11.0 vs. 10.6, p¼ 0.04), and had less smokers (39.4% vs. 54.6%
vs. 48.0%, p<0.01). Adjudicated 1-year all-cause mortality was lower
in the improved GFR group compared to the worsened and no sig-
niﬁcant change groups (15.4% vs. 25.8% vs. 19.1%, p<0.01), as well as
1-year repeat hospitalization (15.1% vs. 30.4 vs. 18.5% %, p<0.01). In a
multivariable analysis, after adjusting for age, gender, BMI, STS score,
diabetes mellitus, COPD, stroke or TIA, baseline ejection fraction,
prior CABG, and baseline GFR, improvement in GFR was associated
with reduced 1-year mortality (HR 0.51, 95% CI 0.34-0.76, p<0.01).
CONCLUSIONS Among those with reduced baseline GFR, TAVR re-
sults in an improvement in GFR in a substantial portion of patients.
Improvement in GFR following TAVR is independently associated
with a reduction in all-cause 1-year mortality in patients with severely
symptomatic AS who are at high surgical risk or are inoperable.
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BACKGROUND The CoreValve self-expanding frame does not require
balloon expansion, but procedural post-dilation of the frame can be
performed in patients with suboptimal acute results. We sought to
deﬁne the incidence of balloon post-dilation (BPD) and the association
